The short version
Just 3 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
imetelstat sodium · IMETELSTAT SODIUM 47 mg/1 · Injection, Powder, Lyophilized, For Solution · Intravenous · Geron Corporation
NDC 82959-0112-01 · 1 VIAL, SINGLE-DOSE in 1 CARTON / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE · NDA · View full market →
Just 3 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Not scored — fragility is computed for NADAC-priced NDCs.
There's no legal definition — it meets 3 of 6 public criteria. Why that matters →
| Type | Number / code | Expires |
|---|---|---|
| exclusivity | ODE-482 | Jun 6, 2031 |
| exclusivity | ODE-482 | Jun 6, 2031 |
| patent | 12171778 | Jun 16, 2039 |
| patent | 12171778 | Jun 16, 2039 |
| patent | 9375485 | Mar 15, 2033 |
| patent | 12442000 | Mar 15, 2033 |
| patent | 9375485 | Mar 15, 2033 |
| patent | 12442000 | Mar 15, 2033 |
| patent | 7494982 | Dec 27, 2026 |
| patent | 7494982 | Dec 27, 2026 |
| patent | 9388415 | Sep 9, 2026 |
| patent | 9388415 | Sep 9, 2026 |
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Catalent Indiana, LLC | IMETELSTAT SODIUM 188 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Geron Corporation | IMETELSTAT SODIUM 188 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Geron Corporation | IMETELSTAT SODIUM 47 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Patheon Italia S.p.A. | IMETELSTAT SODIUM 47 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Rytelo — NDC 82959-0112-01," retrieved September 3, 2026, https://drugdashboards.com/drug/82959011201.
Free to cite with attribution — see how the data is put together.